Cai Jing Wang·2025-12-05 04:07Core Viewpoint - Gaohong Pharmaceutical has submitted an application to list on the Hong Kong Stock Exchange, with CICC and China Merchants Jinling International serving as joint sponsors [1] Company Overview - Gaohong Pharmaceutical is an innovative company focused on developing therapies for patients with autoimmune and inflammatory diseases globally [1] - The company has established a unique advantage in the field of neuroinflammation, particularly with candidate drugs for Alzheimer's disease and Parkinson's disease [1] Product Pipeline - The company has built a differentiated asset portfolio that includes multiple candidates for various autoimmune and neurodegenerative disease indications, with four candidates in clinical stages and several in preclinical stages [1] - Its core product, TLL-018, is the only highly selective TYK2/JAK1 inhibitor globally, expected to be a first-in-class and best-in-class therapy for chronic spontaneous urticaria and rheumatoid arthritis [1] - Gaohong Pharmaceutical is conducting two Phase III registration trials for TLL-018 and plans to submit a New Drug Application (NDA) to the National Medical Products Administration by the end of 2026 [1]